Zuoli Pharmaceutical: Revenue in 2025 is 3.041 billion yuan, and net profit increased by 24.45% year-on-year.

Sali Pharmaceuticals announced that by 2025, its operating income will reach 3.041 billion yuan, an increase of 17.96% year-on-year; net profit attributable to the shareholders of the listed company will reach 632 million yuan, an increase of 24.45% year-on-year. The company has strengthened market expansion based on the advantages of its core products, with all products except traditional Chinese medicine growing, sales growth leading to a decrease in the expense ratio and an improvement in efficiency. In addition, in 2025, the net cash inflow from operating activities was 412 million yuan, an increase of 38.63% year-on-year; the net cash outflow from investment activities was 411 million yuan, an increase of 273.02% year-on-year; and the net cash outflow from financing activities was 117 million yuan, a decrease of 65.46% year-on-year. The shareholders' meeting in 2024 decided to distribute 6 yuan for every 10 shares, which was implemented and completed in May 2025.